Study programme
Classes
- General Biochemistry +1GAF141 | Faculty of Pharmacy in Hradec Králové
- Xenobiochemistry +1GAF237 | Faculty of Pharmacy in Hradec Králové
- Xenobiochemistry - Practical Training +3GAF267 | Faculty of Pharmacy in Hradec Králové
- Selected Chapters from General Biochemistry +1GDEXP04 | Faculty of Pharmacy in Hradec Králové
- The Defense of Doctoral Thesis +1GDEXPODP1 | Faculty of Pharmacy in Hradec Králové
- Xenobiochemistry and Patobiochemistry +1GDEXPSDZ1 | Faculty of Pharmacy in Hradec Králové
Publications
- Pharmacokinetics of flobufen after peroral administration in guinea pigs2002 | Publication without faculty affiliation
- Kinetic feature of enzymes being responsible for flobufen metabolism in guinea pig2002 | Publication without faculty affiliation
- Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux2022 | Faculty of Pharmacy in Hradec Králové
- Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters2022 | Faculty of Pharmacy in Hradec Králové
- Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target effect for the Bcr-Abl tyrosine kinase inhibitor dasatinib2021 | Faculty of Pharmacy in Hradec Králové
- Selective inhibition of aldo-keto reductase 1C3: a novel mechanism involved in midostaurin and daunorubicin synergism2021 | Faculty of Pharmacy in Hradec Králové
- Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors2020 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C32020 | Faculty of Pharmacy in Hradec Králové
- Interactions of antileukemic drugs with daunorubicin reductases: could reductases affect the clinical efficacy of daunorubicin chemoregimens?2020 | Faculty of Pharmacy in Hradec Králové
- Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C32020 | Faculty of Pharmacy in Hradec Králové
Loading network view...